About this trial
Atrial fibrillation is the most common sustained cardiac arrhythmia affecting more than 3% of the adult population. The symptoms of atrial fibrillation can range from asymptomatic to debilitating. It can be permanent in its nature, but also paroxysmal with only short bursts of atrial fibrillation randomly occurring and can therefore remain unnoticed. Atrial fibrillation increases the risk of stroke five fold if left untreated.
Screening for atrial fibrillation in elderly populations above age 65 years can result in detection of new atrial fibrillation cases ranging from 0,5% new AF with a single time-point ECG, up to 30% AF if an implantable loop recorder is inserted for 3 years.
Currently opportunistic screening using pulse palpation, or a single time-point ECG is recommended by the European Society of Cardiology guidelines. Systematic screening in individuals aged 75 or above, or at a high stroke risk should be considered.
Overall, participation in systematic atrial fibrillation screening trials has been shown to be relatively low with almost 50% non-participants. Participants are generally healthier, with higher socioeconomic status, hence the ones who would potentially benefit the most remain absent.
Opportunistic screening has shown promising results with higher participation rates and the possibility of better outreach. There is a lack of data from randomized trials on the difference in participation rates in systematic and opportunistic screening approaches when screening with prolonged ECG monitoring.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Individuals aged 75/76 in 2024 (born 1948, 1949)
Must reside in the region of Värmland
Must be listed at a primary care facility
Disqualifiers
Treatment with oral anti coagulation treatment (OAC)
Contraindications for OAC treatment
Prior atrial fibrillation
Unable to provide consent
Trial design
Parallel
Treatments tested in this trial
Screening invitation mode
BehavioralCluster randomized study to compare mode of invitation
Treatment groups
Trial outcomes
Primary outcomes
Participation in screening
Proportion of invitees participating in screening in each screening arm. The primary hypothesis is that opportunistic screening will increase participation by 25 % compared to systematic screening
Secondary outcomes
AF detection in opportunistic compared to systematic screening
Proportion of participants with newly diagnosed AF in the screening groups
OAC treatment after AF detection
Proportion of participants with AF on OAC treatment after AF detection by manual follow up
Compliance to OAC treatment 1 year after initiation
Proportion of participants with AF on OAC treatment after AF detection
Health economy
Health-economic assessment of costs accrued in the systematic screening group compared to the opportunistic screening group
Sponsors and contacts
Click on the lead sponsor to view all of their trials.